Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Catalent will buy plasmid DNA maker Delphi Genetics

by Rick Mullin
February 28, 2021 | A version of this story appeared in Volume 99, Issue 7

 

Accelerating its move into cell and gene therapy services, Catalent will acquire Delphi Genetics, a drug services firm specializing in plasmid DNA (pDNA). Delphi operates a 1,600 m2 facility in Gosselies, Belgium, close to the MaSTherCell cell therapy facility that Catalent bought last year for $315 million. Catalent says it will launch a pDNA development and manufacturing service at its Rockville, Maryland, facility. Wacker Chemie bought Genopis, a San Diego–based pDNA expert, last month.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.